Intravenous nab-sirolimus was shown in pre-clinical studies to have higher intra-tumoral drug accumulation, mTOR suppression, and tumor growth inhibition compared to its oral counterparts, such as sirolimus and everolimus [37, 38]. Here, MTOR is linked to neoplasm.